Drug lookup | Fillwise

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

All products: Limited Use (codes 310, 393)

Combigan · PIN 09857298 · 0.2% & 0.5% · Oph Sol-10mL Pk

Limited Use — Reason for Use code 310, 393 requiredOntario PIN; no Health Canada record under this code

StatusLimited Use — Reason for Use code 310, 393 required

Write on scriptLU code 310, 393 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 310, 393

Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite

Savings card: innoviCares lists Combigan (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)

1 brand, same coverage

Combigan · DIN 09857298 Manufacturer: Allergan Inc.; listing date 2008-08-28 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check this DIN again

Ministry pays: $23.2900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857298)

Source record

DIN 09857298: Combigan Raw flags: sec12=Y, sec3=Y Item: 523600115; group id 615; item number 1582; lccId 00156; manufacturer id ALL Source form: Oph Sol-10mL Pk; strength: 0.2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $46.5800; ministry $23.2900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857298 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Interchangeable products

Apo-Brimonidine-Timop · DIN 02375311 · $23.2900 Jamp Brimonidine/Timolol · DIN 02531704 · $23.2900

Shortage status: not checked (no credentials)

Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

DICLOFENAC SODIUM

· 6 products · General benefit · strengths: 0.1% · Oph Sol

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

SODIUM CROMOGLYCATE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 2% · Oph Sol

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

AFLIBERCEPT

· 6 products · Limited Use, codes 729, 730, 731 (4), Limited Use, codes 694, 695 (2) · strengths: 2mg/0.05mL, 8mg/0.07mL · Inj Sol-0.05mL Pref Syr (Preservative-Free), Inj Sol-0.07mL Pref Syr, Inj Sol-0.07mL Vial Pk, Sol for Intravitreal Inj-0.05mL Vial Pk

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp

BRINZOLAMIDE & BRIMONIDINE TARTRATE

· 1 products · Limited Use, codes 466, 393 · strengths: 1.0% & 0.2% · Oph Susp-10mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36 and 20 more

Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.

Other drugs whose Health Canada label lists a similar indication: open-angle glaucoma or ocular hypertension, the control of intraocular pressure

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. BRIMONIDINE · Limited Use, codes 171, 172, 387  the control of intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension PM: https://pdf.hres.ca/dpd_pm/00067621.PDF; date NOV 24, 1997; DIN 02236876; fetched 2026-09-10 Product monograph LATANOPROST · Limited Use, codes 171, 172, 387 1 INDICATIONS XALATAN (latanoprost) is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. PM: https://pdf.hres.ca/dpd_pm/00077198.PDF; date SEP 25, 2024; DIN 02231493; fetched 2026-09-10 Product monograph LATANOPROSTENE BUNOD · Limited Use, codes 171, 172, 387 1 INDICATIONS VYZULTA™ (latanoprostene bunod ophthalmic solution, 0.024%) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. PM: https://pdf.hres.ca/dpd_pm/00048990.PDF; date December 27, 2018; DIN 02484218; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

What the Health Canada label says it is for

1 INDICATIONS APO-BRIMONIDINE-TIMOP (brimonidine tartrate 0.2%/timolol 0.5% (as timolol maleate)) ophthalmic solution is indicated for: • the control of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to IOP reducing monotherapy AND when the use of brimonidine tartrate 0.2%/timolol 0.5% (as timolol maleate) ophthalmic solution is considered appropriate. • reduction of long term fluctuation in IOP. In addition to controlling IOP, brimonidine tartrate 0.2%/timolol 0.5% (as timolol maleate) ophthalmic solution reduces long term variability, or fluctuation, in IOP. Together, reductions in IOP and in IOP fluctuation are expected to slow the progression of visual field loss in patients with glaucoma. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): Based on evidence from clinical studies and experience, use in the geriatric population is not associated with any differences… https://pdf.hres.ca/dpd_pm/00070296.PDF PM date: December 14, 2022 Source product: APO-BRIMONIDINE-TIMOP; DIN 02375311; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.